Yuhan Li

Yuhan Li, Yishun Dou, Yue Shi et al.

While text-3D editing has made significant strides in leveraging score distillation sampling, emerging approaches still fall short in delivering separable, precise and consistent outcomes that are vital to content creation. In response, we introduce FocalDreamer, a framework that merges base shape with editable parts according to text prompts for fine-grained editing within desired regions. Specifically, equipped with geometry union and dual-path rendering, FocalDreamer assembles independent 3D parts into a complete object, tailored for convenient instance reuse and part-wise control. We propose geometric focal loss and style consistency regularization, which encourage focal fusion and congruent overall appearance. Furthermore, FocalDreamer generates high-fidelity geometry and PBR textures which are compatible with widely-used graphics engines. Extensive experiments have highlighted the superior editing capabilities of FocalDreamer in both quantitative and qualitative evaluations.

Rohan Agarwal, Wei Zhou, Xiaofeng Wu et al.

Reconstructing a 3D object from a 2D image is a well-researched vision problem, with many kinds of deep learning techniques having been tried. Most commonly, 3D convolutional approaches are used, though previous work has shown state-of-the-art methods using 2D convolutions that are also significantly more efficient to train. With the recent rise of transformers for vision tasks, often outperforming convolutional methods, along with some earlier attempts to use transformers for 3D object reconstruction, we set out to use visual transformers in place of convolutions in existing efficient, high-performing techniques for 3D object reconstruction in order to achieve superior results on the task. Using a transformer-based encoder and decoder to predict 3D structure from 2D images, we achieve accuracy similar or superior to the baseline approach. This study serves as evidence for the potential of visual transformers in the task of 3D object reconstruction.

Yuhan Li, Hongtao Zhang, Keaven Anderson et al.

In the pharmaceutical industry, the use of artificial intelligence (AI) has seen consistent growth over the past decade. This rise is attributed to major advancements in statistical machine learning methodologies, computational capabilities and the increased availability of large datasets. AI techniques are applied throughout different stages of drug development, ranging from drug discovery to post-marketing benefit-risk assessment. Kolluri et al. provided a review of several case studies that span these stages, featuring key applications such as protein structure prediction, success probability estimation, subgroup identification, and AI-assisted clinical trial monitoring. From a regulatory standpoint, there was a notable uptick in submissions incorporating AI components in 2021. The most prevalent therapeutic areas leveraging AI were oncology (27%), psychiatry (15%), gastroenterology (12%), and neurology (11%). The paradigm of personalized or precision medicine has gained significant traction in recent research, partly due to advancements in AI techniques \cite{hamburg2010path}. This shift has had a transformative impact on the pharmaceutical industry. Departing from the traditional "one-size-fits-all" model, personalized medicine incorporates various individual factors, such as environmental conditions, lifestyle choices, and health histories, to formulate customized treatment plans. By utilizing sophisticated machine learning algorithms, clinicians and researchers are better equipped to make informed decisions in areas such as disease prevention, diagnosis, and treatment selection, thereby optimizing health outcomes for each individual.